We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Additional Value of CSF Amyloid-β<sub> {40}</sub> Levels in the Differentiation between FTLD and Control Subjects.
- Authors
Verwey, Nicolaas A.; Kester, Maartje I.; van der Flier, Wiesje M.; Veerhuis, Robert; Berkhof, Hans; Twaalfhoven, Harry; Blankenstein, Marinus A.; Scheltens, Philip; Pijnenburg, Yolande A. L.
- Abstract
To determine the additional value of cerebrospinal fluid (CSF) amyloid-β {1-40} (Aβ {40}) next to amyloid-β {1-42} (β {42}), total tau (Tau), and tau phosphorylated at threonine-181 (pTau) to distinguish patients with frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), and controls, we measured CSF levels of Aβ {40}, Aβ {42}, pTau, and Tau in 55 patients with FTLD, 60 with AD, and 40 control subjects. Logistic regression was used to identify biomarkers that best distinguished the groups. Additionally, a decision tree (cost=test method; Matlab 7.7) was used to predict diagnosis selecting the best set of biomarkers with the optimal cut-off. Logistic regression showed that Aβ {42} and pTau CSF levels provided optimal distinction between AD and FTLD. A combination of Aβ {42}, Tau, and Aβ {40} optimally discriminated FTLD from controls and AD from controls. The decision tree used Aβ {42} (cut-off 578 pg/ml) to identify AD (positive predictive value (PPV) 97%), followed by Tau (cut-off 336 pg/ml) to identify FTLD (PPV 67%), and in the last step, Aβ {40} (cut-off 10 ng/ml) was used to differentiate controls (PPV 68%). Applying CSF Aβ{40} levels in the model, the PPV of diagnosis increased to 75% as opposed to 70% when only Aβ {42} and Tau were used. CSF Aβ {40} levels added to the conventional CSF biomarkers increases the potential to discriminate subjects with dementia from controls. Our findings favor the implementation of CSF Aβ {40} in differential diagnosis between FTLD, AD, and control subjects.
- Subjects
AMSTERDAM (Netherlands); NETHERLANDS; AMYLOID beta-protein; CEREBROSPINAL fluid; BIOMARKERS; ALZHEIMER'S disease; FRONTOTEMPORAL dementia; CLINICAL trials
- Publication
Journal of Alzheimer's Disease, 2010, Vol 20, Issue 2, p445
- ISSN
1387-2877
- Publication type
Article
- DOI
10.3233/JAD-2010-1392